932-P: Impacts of Glucose Variability on the Correlation between Estimated Hemoglobin A1c and Measured Glycated Hemoglobin A1c in Patients with Type 2 Diabetes

Abstract

Objectives: With the mean blood glucose obtained from a continuous glucose monitoring system (iPro2), an estimated glycated hemoglobin A1c (eA1c) could be calculated by the equation. If the eA1c is highly matched the measured A1c, it can be widely used in day-to-day clinical practice. Therefore, this study aimed to compare the eA1c from iPro2 and the measured A1c in non-critically ill inpatients with type 2 diabetes (T2D) to determine whether eA1c from iPro2 is applicable to this population. Methods: Data were collected from the patients withT2D between July 2017 and December 2018 in our department. Patients with abnormal hemoglobin levels and acute diabetic complications were excluded. After a 48-hour to 72-hour continuous glucose monitoring with iPro2, values of eA1c obtained from iPro2 were recorded. The corresponding A1c values of the patients were measured by high performance liquid chromatography. Mean amplitude of glycemic excursions (MAGE), an index representing glucose variability, was assessed with data from iPro2. Patients were categorized into four groups based on the quartile categories of MAGE. Spearman correlation was used to analyze the correlation between eA1c and the measured A1c within the quartile categories of MAGE. Results: A total of 42 reports from 42 patients with T2D were studied. The patients were 54.48(13.47) [mean (SD)] years old, with the diabetes duration of 8.71(6.34) years, measured A1c of 6.66 (1.06) % and eA1c of 6.20(0.66) %. There was a positive correlation between eA1c and measured A1c (r= 0.57, p=0.0001). Correlation coefficients of eA1c and measured A1c was 0.70 (p=0.017), 0.63 (p=0.049), 0.56 (p=0.096) and 0.58 (p=0.06) for the first, second, third and fourth MAGE quartile, respectively. Conclusions: The correlation between eA1c and measured A1c was altered by MAGE. Value of eA1c obtained from iPro2 should not be used in T2D patients with high glucose variability. Disclosure D. Yang: None. B. Lin: None. W. Xu: None. X. Yang: None. B. Yao: None.